Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$11.00 USD
-0.11 (-0.99%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $11.00 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
ROIV 11.00 -0.11(-0.99%)
Will ROIV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ROIV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ROIV
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates
ROIV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Stock Market News for Nov 14, 2023
Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data
Roivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last?
Other News for ROIV
3 Best Stocks to Buy Now, 7/19/2024, According to Top Analysts
Piper Sandler Keeps Their Buy Rating on Roivant Sciences (ROIV)
Buy Rating on Roivant Sciences Amid Anticipation of High-Potential Phase 2 Asset Reveal
Tracking Baker Brothers Portfolio - Q1 2024 Update
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS), Replimune Group (REPL) and Roivant Sciences (ROIV)